VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AVNS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AVNSAvanos Medical, Inc.
$24.92$1.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

AVNS logoAvanos Medical, Inc.(AVNS)Earnings, Financials & Key Ratios

AVNS•NYSE
$24.92
Price updated Jul 7, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryRespiratory and sleep therapy devices
AboutAvanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Show more
  • Revenue$701M+1.9%
  • EBITDA-$33M-138.1%
  • Net Income-$68M+82.7%
  • EPS (Diluted)-1.46+82.9%
  • Gross Margin49.77%-10.2%
  • EBITDA Margin-4.65%-137.4%
  • Operating Margin-8.78%-251.1%
  • Net Margin-9.68%+83.0%
  • ROE-8.45%+77.7%

AVNS Price & Volume

Avanos Medical, Inc. (AVNS) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Volatility Masks Structural Turnaround Efforts

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Persistent operating margin volatility

Key Thesis Takeaways

  • Avanos Medical is currently navigating a challenging transition characterized by significant asset downsizing and inconsistent profitability, as evidenced by a $774.8 million accumulated deficit.
  • While the company maintains a conservative debt-to-equity ratio of 0.18, the lack of sustained operating leverage and recurring margin compression suggest that the core business model remains under pressure.
  • Investors should monitor whether the company can stabilize its erratic cash flow and improve its 4.9% operating margin before committing capital to this turnaround play.

Verdict Logic

the company's inability to generate consistent profitability, highlighted by a -49.4% operating margin in 2025Q4, warrants caution despite a healthy 2.48 current ratio.

AVNS Growth Metrics

Avanos Medical, Inc. (AVNS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-7.77%
5 Years-0.38%
3 Years0.83%
TTM3.87%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM81.96%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM82.07%

Return on Capital

10 Years1.1%
5 Years1.92%
3 Years0.34%
Last Year-6.5%

AVNS Recent Earnings

Avanos Medical, Inc. (AVNS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$0.22+37.5%
$0.16
Rev
$182M+7.2%
$170M
Q1 2026
Feb 24, 2026
Metric
Actual
Est
EPS
$0.29+20.8%
$0.24
Rev
$181M+3.5%
$175M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$0.22+83.3%
$0.12
Rev
$178M+8.1%
$165M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.17-5.6%
$0.18
Rev
$175M+4.5%
$168M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$0.22vs $0.16+37.5%
$182Mvs $170M+7.2%
Q1 2026Feb 24, 2026
$0.29vs $0.24+20.8%
$181Mvs $175M+3.5%
Q4 2025Nov 5, 2025
$0.22vs $0.12+83.3%
$178Mvs $165M+8.1%
Q3 2025Aug 5, 2025
$0.17vs $0.18-5.6%
$175Mvs $168M+4.5%
Based on last 12 quarters of dataView full earnings history →

Latest AVNS News

Recent stock market news and headlines for Avanos Medical, Inc. (AVNS)

PRNewsWire·6 days ago
Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger

ALPHARETTA, Ga. and NEW YORK, July 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos") and American Industrial Partners ("AIP") jointly announced the receipt of all required regulatory approvals to complete the pending acquisition of Avanos by affiliates of investment funds advised by AIP (the "Merger").

GuruFocus·Jun 25, 2026
Are CRBG, EQH, AVNS Obtaining Fair Deals for their Shareholders?

Are CRBG, EQH, AVNS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026

Zacks Investment Research·Jun 24, 2026
Reasons to Retain Avanos Medical Stock in Your Portfolio for Now

AVNS' SNS momentum, Nexus Medical integration and AIP deal support growth, but tariff costs, margin pressure and PM&R weakness remain headwinds.

Peers Comparison

Key metrics vs top competitors for Avanos Medical, Inc. (AVNS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AVNS logoAVNSAvanos Medical, Inc.Current
$24.92$1.17B-17.071.95%-9.68%-8.45%—
MMSI logoMMSIMerit Medical Systems, Inc.
$72.14$4.3B33.8711.66%9.03%8.95%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
ITGR logoITGRInteger Holdings Corporation
$91.90$3.16B31.807.57%7.67%8.23%—
ATRC logoATRCAtriCure, Inc.
$32.80$1.66B-136.6714.88%-0.83%-0.95%—
NTRA logoNTRANatera, Inc.
$281.27$40.28B-185.0535.9%-9.05%-15.13%—

Compare AVNS vs Peers

Avanos Medical, Inc. (AVNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MMSI

Most directly comparable listed peer for AVNS.

Scale Benchmark

vs SYK

Larger-name benchmark to compare AVNS against a more recognizable public peer.

Peer Set

Compare Top 5

vs MMSI, NVCR, ITGR, ATRC

AVNS SEC Filings & Documents

Avanos Medical, Inc. (AVNS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 5, 2026·SEC

Material company update

Apr 14, 2026·SEC

Material company update

Mar 12, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 5, 2025·SEC

Get notified when AVNS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AVNS Frequently Asked Questions

Avanos Medical, Inc. (AVNS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Avanos Medical, Inc.'s revenue?

Avanos Medical, Inc. (AVNS) reported $715.9M in revenue for fiscal year 2025. This represents a 57% decrease from $1.68B in 2012.

How fast is Avanos Medical, Inc. growing?

Avanos Medical, Inc. (AVNS) grew revenue by 1.9% over the past year. Growth has been modest.

Is AVNS profitable?

Avanos Medical, Inc. (AVNS) reported a net loss of $69.4M for fiscal year 2025.

Dividend & Returns
What is AVNS's return on equity?

Avanos Medical, Inc. (AVNS) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.

What is Avanos Medical, Inc.'s free cash flow?

Avanos Medical, Inc. (AVNS) generated $24.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in AVNS back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →